Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs? Livio GarattiniFrancesca GhislandiMilene Rangel Da Costa Commentary 21 August 2015 Pages: 1241 - 1244
Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease Zobair M. YounossiLinda Henry Leading Article 02 August 2015 Pages: 1245 - 1253
Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice James F. O’MahonyAnthony T. NewallJoost van Rosmalen Practical Application Open access 25 June 2015 Pages: 1255 - 1268
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence Christina GiannopoulouEleftherios SiderisClaire McKenna Review Article 05 June 2015 Pages: 1269 - 1279
Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making? Jonathan KarnonAndrew Partington Original Research Article 23 June 2015 Pages: 1281 - 1288
Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment Liesbet van de WeteringJob van ExelWerner B. F. Brouwer Original Research Article Open access 01 August 2015 Pages: 1289 - 1300
Cost Effectiveness of Falls and Injury Prevention Strategies for Older Adults Living in Residential Aged Care Facilities Jody L. ChurchMarion R. HaasStephen Goodall Original Research Article 05 August 2015 Pages: 1301 - 1310
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland Florian S. GutzwillerAlena M. PfeilMatthias Schwenkglenks Original Research Article Open access 03 September 2015 Pages: 1311 - 1324
